Joint (NASDAQ: JYNT) and Diplomat Pharmacy (NYSE:DPLO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.
Volatility and Risk
Joint has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Diplomat Pharmacy has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
45.2% of Joint shares are owned by institutional investors. Comparatively, 72.2% of Diplomat Pharmacy shares are owned by institutional investors. 6.1% of Joint shares are owned by company insiders. Comparatively, 30.2% of Diplomat Pharmacy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a summary of recent ratings and target prices for Joint and Diplomat Pharmacy, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Joint currently has a consensus price target of $6.15, indicating a potential upside of 23.74%. Diplomat Pharmacy has a consensus price target of $20.31, indicating a potential downside of 2.20%. Given Joint’s stronger consensus rating and higher possible upside, analysts plainly believe Joint is more favorable than Diplomat Pharmacy.
Valuation and Earnings
This table compares Joint and Diplomat Pharmacy’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Joint||$20.52 million||3.27||-$15.17 million||($0.69)||-7.20|
|Diplomat Pharmacy||$4.41 billion||0.32||$28.27 million||$0.12||173.08|
Diplomat Pharmacy has higher revenue and earnings than Joint. Joint is trading at a lower price-to-earnings ratio than Diplomat Pharmacy, indicating that it is currently the more affordable of the two stocks.
This table compares Joint and Diplomat Pharmacy’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Diplomat Pharmacy beats Joint on 9 of the 13 factors compared between the two stocks.
Joint Company Profile
The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention. The Company has approximately 310 franchised, company-owned, or managed clinics in operation in over 30 states. In addition to its approximately 310 operating clinics, the Company has granted franchises either directly or through its regional developers for an additional over 170 clinics. The Company offers a range of membership and wellness packages. Each patient’s records are digitally updated for ready retrieval in its data storage system by its chiropractors in compliance with various applicable medical records security and privacy regulations.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s patient care system is used to coordinate and track patient adherence and safety.
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.